(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) With so much uncertainty over how broad and severe the next wave of H1N1 influenza could be, now is the time to focus on the two top goals of saving and sustaining lives, Dr. Julie Gerberding, former director of the US Centers for Disease Control and Prevention (CDC), told business groups today.
(CIDRAP News) Leading public health officials and experts have sharply rejected charges from some European officials that pharmaceutical companies used exaggerated claims about the H1N1 pandemic threat to scare governments into buying unnecessary stockpiles of vaccines.
(CIDRAP News) A recent case-control study estimates that the adjuvanted pandemic H1N1 influenza vaccine used in Canada was effective 93% of the time, a substantially higher figure than seen in several other studies and one that has raised some eyebrows among other flu vaccine researchers.